ThermoGenesis Holdings (THMO) AI Stock Analysis

330 Followers

ThermoGenesis Holdings

(Other OTC:THMO)

Select Model

Rating:39Underperform

Action:N/A

Date:01/02/25

ThermoGenesis Holdings is facing significant financial and operational challenges, with negative equity, declining revenues, and liquidity issues. The absence of technical analysis data and meaningful valuation metrics further complicates the outlook. The neutral impact of the earnings call does not offset the overall negative financial performance.

Positive Factors

Business Model StrengthThermoGenesis's focus on automated cell processing technologies positions it well in the growing regenerative medicine field, offering potential for long-term revenue growth as demand for efficient cell therapy solutions increases.

Negative Factors

Financial InstabilityNegative equity indicates a precarious financial position, raising concerns about the company's solvency and ability to sustain operations without restructuring or additional capital.

ThermoGenesis Holdings (THMO) vs. SPDR S&P 500 ETF (SPY)

Not enough price history over this period.

Market Cap: $1,585
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 0.0
Beta (1Y): 136.07
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 25
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

ThermoGenesis Holdings Business Overview & Revenue Model

Company Description

ThermoGenesis Holdings, Inc., founded in 1986 and based in Rancho Cordova, California, is a global innovator specializing in automated systems for cell-banking, cell-processing, and cell-based therapeutic applications. The company's advanced solution...

How the Company Makes Money

ThermoGenesis Holdings generates revenue through the sale of its bioprocessing and cell therapy equipment, including automated cell separation systems and cryopreservation solutions. The company also earns income from licensing its proprietary techno...

ThermoGenesis Holdings Risk Analysis

ThermoGenesis Holdings disclosed 46 risk factors in its most recent earnings report. ThermoGenesis Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.We may not be able to maintain our listing on The Nasdaq Capital Market and it may become more difficult to sell our stock in the public market.Q1, 2024

ThermoGenesis Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

THMO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AEMD	47Neutral	$8.49M	-0.49	-123.09%	―	―	87.54%
HSCS	46Neutral	$14.86M	-0.92	-816.25%	―	-27.70%	61.44%
BJDX	44Neutral	$9.47M	-0.06	-125.01%	―	―	93.91%
MOVE	41Neutral	$196.26M	-0.54	-9.67%	―	843.62%	21.98%
THMO	39Underperform	$1,585	0.00	-1367.44%	―	―	―

* Healthcare Sector Average

Performance Comparison

THMO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
THMO	Thermogenesis Holdings Inc	―	―	―
AEMD	Aethlon	5.80	-15.50	-72.77%
MOVE	Corvex, Inc.	6.65	2.75	70.43%
BJDX	Bluejay Diagnostics, Inc.	2.21	-23.23	-91.31%
HSCS	Heart Test Laboratories, Inc.	2.95	0.22	8.06%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 02, 2025

ThermoGenesis Holdings AI Stock Analysis